CA3126302A1 - Recombinant anti-human pd-1 antibody and application thereof - Google Patents

Recombinant anti-human pd-1 antibody and application thereof Download PDF

Info

Publication number
CA3126302A1
CA3126302A1 CA3126302A CA3126302A CA3126302A1 CA 3126302 A1 CA3126302 A1 CA 3126302A1 CA 3126302 A CA3126302 A CA 3126302A CA 3126302 A CA3126302 A CA 3126302A CA 3126302 A1 CA3126302 A1 CA 3126302A1
Authority
CA
Canada
Prior art keywords
seq
oas
cii
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3126302A
Other languages
English (en)
French (fr)
Inventor
Jinchao Zhang
Rongjuan WANG
Shasha JIAO
Shuang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabwell Shanghai Bioscience Co Ltd
Original Assignee
Mabwell Shanghai Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabwell Shanghai Bioscience Co Ltd filed Critical Mabwell Shanghai Bioscience Co Ltd
Publication of CA3126302A1 publication Critical patent/CA3126302A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3126302A 2019-01-10 2020-01-10 Recombinant anti-human pd-1 antibody and application thereof Pending CA3126302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910022548.9 2019-01-10
CN201910022548.9A CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用
PCT/CN2020/071353 WO2020143749A1 (zh) 2019-01-10 2020-01-10 重组抗人pd-1抗体及其应用

Publications (1)

Publication Number Publication Date
CA3126302A1 true CA3126302A1 (en) 2020-07-16

Family

ID=71521975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3126302A Pending CA3126302A1 (en) 2019-01-10 2020-01-10 Recombinant anti-human pd-1 antibody and application thereof

Country Status (8)

Country Link
US (1) US20230104769A1 (cg-RX-API-DMAC7.html)
EP (1) EP3919514A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022517216A (cg-RX-API-DMAC7.html)
KR (1) KR20210113635A (cg-RX-API-DMAC7.html)
CN (1) CN111423510B (cg-RX-API-DMAC7.html)
CA (1) CA3126302A1 (cg-RX-API-DMAC7.html)
TW (1) TW202043271A (cg-RX-API-DMAC7.html)
WO (1) WO2020143749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
CN114907478A (zh) * 2021-02-08 2022-08-16 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
WO2025102227A1 (zh) * 2023-11-14 2025-05-22 成都盛世君联生物技术有限公司 一种抗pd-1抗体及其生物材料和产品

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN106699889A (zh) * 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
CN109152798B (zh) * 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
KR20220114063A (ko) * 2019-12-13 2022-08-17 큐진 인크. 신규한 인터루킨-15 (il-15) 융합 단백질 및 이의 용도
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof

Also Published As

Publication number Publication date
JP2022517216A (ja) 2022-03-07
KR20210113635A (ko) 2021-09-16
EP3919514A4 (en) 2022-12-07
TW202043271A (zh) 2020-12-01
WO2020143749A1 (zh) 2020-07-16
US20230104769A1 (en) 2023-04-06
CN111423510B (zh) 2024-02-06
EP3919514A1 (en) 2021-12-08
CN111423510A (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
JP7724332B2 (ja) クローディン18.2結合部分およびその利用
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
JP7407841B2 (ja) クローディン18a2に対する抗体及びその応用
JP2026062933A (ja) Cd73特異的結合分子及びその使用
EP3575318A1 (en) Anti-pd-1 antibody and use thereof
CN115461372A (zh) 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
US20230104769A1 (en) Recombinant anti-human pd-1 antibody and application thereof
CN114763385B (zh) 靶向ror1的抗体及其用途
JP2025506318A (ja) 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用
JP2021513331A (ja) 抗b7−h4抗体、その抗原結合断片及びその医薬用途
KR20220121808A (ko) 항-pd-l1/항-b7-h3 다중특이적 항체 및 이의 용도
US20240352153A1 (en) Pharmaceutical composition and use
JP7780521B2 (ja) 抗tigit抗体、その医薬組成物及び用途
EP4435010A1 (en) Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
KR20180101483A (ko) 치료적 항-cd9 항체
CN118946592A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
KR20220167331A (ko) 항-flt3 항체 및 조성물
CN117999284A (zh) 靶向tigit的单克隆抗体
HK40062048B (en) Antibody against claudin 18a2 and use thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226